di , 05/02/2024

Investment Marks a Significant Milestone in Advancing AI-Based Arrhythmia Care

SAN DIEGO–(BUSINESS WIRE)– Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science. This funding underscores investor confidence in Vektor’s vision and ability to successfully execute its mission to revolutionize arrhythmia care.

“The medical community is being confronted with the necessity for change. With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency,” said Rob Krummen, CEO of Vektor Medical. “vMap presents a solution to this challenge. Leading electrophysiologists (EPs) around the U.S. are utilizing vMap to streamline ablation procedures and improve patient outcomes. With the investment from Solas and TVM, we can expand access to this groundbreaking technology.”

Funding will support the commercialization of vMap®, Vektor’s AI-based arrhythmia analysis tool, which is transforming how EPs approach ablation procedures. To bolster this expansion, Vektor will increase clinical support and drive additional clinical studies to showcase the technology’s impact and inform future innovation as well as continue efforts to secure reimbursement.

“At Solas, we invest in game-changing healthcare innovation and strong leadership teams committed to creating meaningful patient impact,” said Dr. David Adair, Managing Director of Solas BioVentures. “Vektor is addressing a massive problem in the cardiac arrhythmia space, giving millions of patients a chance to lead healthy lives free from this debilitating disease once again. We are thrilled to partner with the team and support Vektor’s unwavering commitment to challenging the status quo across the entire cardiac arrhythmia pathway, making it easier and faster for physicians and health systems to access this breakthrough technology.”

vMap is the only FDA-cleared, non-invasive AI-based solution for arrhythmia localization and analysis, utilizing a 12-lead ECG. vMap provides information to a physician to better understand arrhythmia sources and unlock actionable insights, enabling physicians to streamline their procedures and more appropriately treat their patients.

“Changing the standard of care demands a unique and transformative approach,” said Dr. Luc Marengère, Managing Partner at TVM Capital Life Science. “vMap has been embraced by EPs focused on excellence. With increased resources, Vektor will scale adoption across the US and Europe. Patients and healthcare providers deserve better and Vektor is ushering in that transition. We’re thrilled to invest and partner with Vektor to drive this important healthcare transformation.”

About Vektor Medical

Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.

About Solas BioVentures

Solas BioVentures invests exclusively in the life science industry, focusing on early-stage biotech, medtech and digital health companies. The Solas investment team combines decades of clinical, regulatory and operating experience across different verticals in healthcare. Founded in Chattanooga, TN, Solas is proud of its southern roots and founder-centric patient-focused approach to foster breakthrough medicine and technology innovation. Solas puts patients first.

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.


Media Contact
Stacey Holifield
(617) 233-3873